TWST Valuation

Twist Bioscience Corp

Add to Watchlist

Advanced Chart

31.000

-0.87(-2.730%)1D

TWST Relative Valuation

TWST's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TWST is overvalued; if below, it's undervalued.

Historical Valuation

Twist Bioscience Corp (TWST) is now in the Overvalued zone, suggesting that its current forward PS ratio of 31.32 is considered Overvalued compared with the five-year average of -17.89. The fair price of Twist Bioscience Corp (TWST) is between 5.89 to 14.85 according to relative valuation methord. Compared to the current price of 31.87 USD , Twist Bioscience Corp is Overvalued By 114.65%.

Relative Value

Fair Zone

5.89-14.85

Current Price：31.87

114.65%

Overvalued

-21.26

Trailing

Forward

-48.61

EV/EBITDA

Twist Bioscience Corp. (TWST) has a current EV/EBITDA of -48.61. The 5-year average EV/EBITDA is -18.01. The thresholds are as follows: Strongly Undervalued below -44.72, Undervalued between -44.72 and -31.36, Fairly Valued between -4.66 and -31.36, Overvalued between -4.66 and 8.70, and Strongly Overvalued above 8.70. The current Forward EV/EBITDA of -48.61 falls within the Strongly Undervalued range.

-16.77

EV/EBIT

Twist Bioscience Corp. (TWST) has a current EV/EBIT of -16.77. The 5-year average EV/EBIT is -15.57. The thresholds are as follows: Strongly Undervalued below -40.11, Undervalued between -40.11 and -27.84, Fairly Valued between -3.29 and -27.84, Overvalued between -3.29 and 8.98, and Strongly Overvalued above 8.98. The current Forward EV/EBIT of -16.77 falls within the Historic Trend Line -Fairly Valued range.

31.87

Twist Bioscience Corp. (TWST) has a current PS of 31.87. The 5-year average PS is 14.67. The thresholds are as follows: Strongly Undervalued below -16.72, Undervalued between -16.72 and -1.03, Fairly Valued between 30.36 and -1.03, Overvalued between 30.36 and 46.05, and Strongly Overvalued above 46.05. The current Forward PS of 31.87 falls within the Overvalued range.

559.05

P/OCF

Twist Bioscience Corp. (TWST) has a current P/OCF of 559.05. The 5-year average P/OCF is 122.90. The thresholds are as follows: Strongly Undervalued below -1420.17, Undervalued between -1420.17 and -648.64, Fairly Valued between 894.43 and -648.64, Overvalued between 894.43 and 1665.97, and Strongly Overvalued above 1665.97. The current Forward P/OCF of 559.05 falls within the Historic Trend Line -Fairly Valued range.

183.21

P/FCF

Twist Bioscience Corp. (TWST) has a current P/FCF of 183.21. The 5-year average P/FCF is -13.86. The thresholds are as follows: Strongly Undervalued below -112.17, Undervalued between -112.17 and -63.01, Fairly Valued between 35.29 and -63.01, Overvalued between 35.29 and 84.44, and Strongly Overvalued above 84.44. The current Forward P/FCF of 183.21 falls within the Strongly Overvalued range.

Twist Bioscience Corp (TWST) has a current Price-to-Book (P/B) ratio of 3.94. Compared to its 3-year average P/B ratio of 3.58 , the current P/B ratio is approximately 9.95% higher. Relative to its 5-year average P/B ratio of 5.10, the current P/B ratio is about -22.71% higher. Twist Bioscience Corp (TWST) has a Forward Free Cash Flow (FCF) yield of approximately -3.63%. Compared to its 3-year average FCF yield of -8.97%, the current FCF yield is approximately -59.48% lower. Relative to its 5-year average FCF yield of -7.57% , the current FCF yield is about -51.96% lower.

4.01

P/B

Median3y

3.58

Median5y

5.10

-3.57

FCF Yield

Median3y

-8.97

Median5y

-7.57

Competitors Valuation Multiple

The average P/S ratio for TWST's competitors is 20.41, providing a benchmark for relative valuation. Twist Bioscience Corp Corp (TWST) exhibits a P/S ratio of 31.87, which is 56.13% above the industry average. Given its robust revenue growth of 17.91%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

TWST.O

Twist Bioscience Corp

Edgewise Therapeutics Inc

Aurinia Pharmaceuticals Inc

Performance Decomposition

Market capitalization of TWST decreased by 35.20% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -13.26 to -22.16.

The secondary factor is the Revenue Growth, contributed 17.91%to the performance.

Overall, the performance of TWST in the past 1 year is driven by P/E Change. Which is more unsustainable.

17.91%

81.46M → 96.06M

Revenue Growth

-120.21%

-105.04 → 21.23

Margin Expansion

67.10%

-13.26 → -22.16

P/E Change

-35.20%